SCIENTIFIC EVIDENCE

Distinct immune microenvironment in HER2-low triple-negative breast cancer underlies inferior response to immunotherapy

NPJ precision oncology

Ge H, Wei Y, Qi Y, Mo H, Zhai J, Zeng C, Sun X, Ma F.

Publication Overview

Key findings, Countstar context, and access to the original paper.

2026

Cancer Research

Immunology

Key Finding

This study examines tumor immunity in HER2-low breast cancer.

Countstar Connection

The paper identifies the Countstar Rigel S2 in its documentation for this study of tumor immunity in HER2-low breast cancer.

Stay Connected to

Get new publications, application notes, cell analysis insights, and Countstar updates delivered to your inbox.

Meet us online